Search

Pfizer

Suletud

SektorTervishoid

24.85 -0.2

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

24.65

Max

25

Põhinäitajad

By Trading Economics

Sissetulek

4.3B

2.7B

Müük

-3.1B

14B

P/E

Sektori keskmine

19.186

62.58

Aktsiakasum

0.75

Dividenditootlus

6.87

Kasumimarginaal

18.656

Töötajad

75,000

EBITDA

4.3B

5B

Soovitused

By TipRanks

Soovitused

Neutraalne

12 kuu keskmine prognoos

+14.83% upside

Dividendid

By Acuity

Dividenditootlus

Sektori keskmine

6.87%

2.19%

Järgmine tulemuste avaldamine

4. aug 2026

Järgmine dividendimakse kuupäev

1. sept 2026

Järgmine aktsia dividendi kuupäev (ex-date)

24. juuli 2026

Turustatistika

By TradingEconomics

Turukapital

-8.5B

141B

Eelmine avamishind

25.05

Eelmine sulgemishind

24.85

Uudiste sentiment

By Acuity

45%

55%

130 / 340 Pingereas Healthcare

Pfizer Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

21. juuli 2026, 23:11 UTC

News

Pfizer Inc. options trading showed light volume, with calls outpacing puts and a put/call ratio of 0.56. Shares were little changed in after-market hours.

20. juuli 2026, 23:16 UTC

Pfizer Inc shares are higher in after-market trading, maintaining above their 20-day moving average despite broader market pressures from rising treasury yields.

Võrdlus sarnastega

Hinnamuutus

Pfizer Prognoos

Hinnasiht

By TipRanks

14.83% tõus

12 kuu keskmine prognoos

Keskmine 28.42 USD  14.83%

Kõrge 35 USD

Madal 25 USD

Põhineb 23 Wall Streeti analüütiku instrumendi Pfizer 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

23 ratings

7

Osta

14

Hoia

2

Müü

Sentiment

By Acuity

130 / 340 Pingereas Tervishoid

Uudiste sentiment

Languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Pfizer

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as has strategic clinical collaboration with Acepodia Inc. for the development of antibody-cell conjugation-based cell therapies in autoimmune diseases. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
help-icon Live chat